aTyr Pharma, Inc. (ATYR)

Market Cap	53.43M -81.9%
Revenue (ttm)	190,000 -19.1%
Net Income	-70.03M
EPS	-0.73
Shares Out	98.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,497,429
Open	0.5354
Previous Close	0.4874
Day's Range	0.5200 - 0.5581
52-Week Range	0.3950 - 7.2900
Beta	0.66
Analysts	Buy
Price Target	2.86 (+424.87%)
Earnings Date	May 15, 2026

About ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: ATYR
• Website: https://atyrpharma.com

Financial Performance

In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.

Analyst Summary

According to 9 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $2.86, which is an increase of 424.87% from the latest price.

Price Target

$2.86

(424.87% upside)

Analyst Consensus: Buy